In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars – Commercial Best Practices In The Age Of Sustainability

Key Rules Of The Road’ For Biosimilar Developers

Executive Summary

If there is one fact that even the most casual observer of the pharma industry is aware of, it is that biologics are the leading growth engine of global medicines spending. According to IQVIA, revenues from biologics increased by 70% during 2011-2016 to reach $232bn, accounting for roughly 20-22% of total pharmaceutical spending.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV124287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel